Ildong Pharmaceutical Officially Launches Yunovia, a Dedicated R&D Subsidiary

Yunovia, a dedicated research and development (R&D) subsidiary of Ildong Pharmaceutical, has officially launched.

On the 2nd, Ildong Pharmaceutical announced that President Seojin Sik (former COO of Ildong Pharmaceutical) and President Choi Seonggu (former head of Ildong Pharmaceutical’s R&D division) will serve as the inaugural co-CEOs of Yunovia. Yunovia plans to pursue business strategies such as investment attraction, open innovation, and licensing out, alongside the development of existing new drug projects and pipelines.

President Seo Jin-sik (left), President Choi Seong-gu (Photo by Ildong Pharmaceutical)

Yunovia has secured 6 to 7 core new drug pipelines in areas including metabolic diseases, degenerative diseases, liver diseases, gastrointestinal diseases, and ophthalmic diseases. Including ongoing new drug research projects and platform technologies in fields such as cancer, cardiovascular diseases, neurological and psychiatric disorders, infectious diseases, and pulmonary and respiratory diseases, as well as microbiome projects, the company currently holds about 25 pipelines.

Among these, the metabolic disease drug candidate ‘ID110521156’, a GLP-1 receptor agonist targeting type 2 diabetes and obesity, and the A1·A2A receptor antagonist ‘ID119040338’, being developed as a treatment for Parkinson’s disease, a degenerative disorder, are reportedly attracting interest from numerous global companies, according to the company.

A Yunovia representative stated, “Yunovia is differentiated by starting in a prepared state, inheriting the R&D capabilities and assets cultivated at Ildong Pharmaceutical. We will establish ourselves as a specialized R&D company with a sustainable virtuous cycle structure, leading with competitive and promising pipelines.”

This content was produced with the assistance of AI translation services.